Biosolution Co.Ltd Total Liabilities
Biosolution Co.Ltd total liabilities. Based on the latest financial reports, Biosolution Co.Ltd (086820) has total liabilities worth ₩36.25 Billion KRW (≈ $24.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 086820 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biosolution Co.Ltd (2015–2024)
Total liabilities of Biosolution Co.Ltd from 2015 to 2024. This chart illustrates how Biosolution Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 086820 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Biosolution Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Biosolution Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aspire Mining Ltd
AU:AKM
|
Australia | AU$678.63K |
|
Min Aik Precision Industrial Co Ltd
TW:4545
|
Taiwan | NT$1.26 Billion |
|
ATM Grupa S.A.
WAR:ATG
|
Poland | zł111.62 Million |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
Indonesia | Rp8.56 Trillion |
|
Rayence Co. Ltd
KQ:228850
|
Korea | ₩29.87 Billion |
|
Sirios Resources Inc.
V:SOI
|
Canada | CA$6.42 Million |
|
Precot Limited
NSE:PRECOT
|
India | Rs4.75 Billion |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
Thailand | ฿385.79 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Biosolution Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Biosolution Co.Ltd.
Liquidity & Leverage Metrics
Biosolution Co.Ltd Total Liabilities Ratios Explained
Biosolution Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosolution Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosolution Co.Ltd (2015–2024)
The table below shows the annual total liabilities of Biosolution Co.Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩36.21 Billion ≈ $24.54 Million |
-27.90% |
| 2023-12-31 | ₩50.22 Billion ≈ $34.03 Million |
+4.72% |
| 2022-12-31 | ₩47.96 Billion ≈ $32.50 Million |
-2.91% |
| 2021-12-31 | ₩49.39 Billion ≈ $33.47 Million |
+1475.96% |
| 2020-12-31 | ₩3.13 Billion ≈ $2.12 Million |
-15.54% |
| 2019-12-31 | ₩3.71 Billion ≈ $2.51 Million |
-2.39% |
| 2018-12-31 | ₩3.80 Billion ≈ $2.58 Million |
+28.41% |
| 2017-12-31 | ₩2.96 Billion ≈ $2.01 Million |
+9.73% |
| 2016-12-31 | ₩2.70 Billion ≈ $1.83 Million |
+12.64% |
| 2015-12-31 | ₩2.40 Billion ≈ $1.62 Million |
-- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more